Drug profile · INN
tivozanib hydrochloride monohydrate
FOTIVDA
tivozanib hydrochloride monohydrate (FOTIVDA) is a platelet-derived growth factor receptor beta inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01EK03
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tivozanib hydrochloride monohydrate
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
tivozanib hydrochloride monohydrate (FOTIVDA) is a platelet-derived growth factor receptor beta inhibitor.
Key facts
INN tivozanib hydrochloride monohydrate
Brand FOTIVDA
Mechanism Platelet-derived growth factor receptor beta inhibitor
Target Platelet-derived growth factor receptor beta
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EK03
Mechanism of action
Platelet-derived growth factor receptor beta inhibitor
Primary target: Platelet-derived growth factor receptor beta
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tivozanib hydrochloride monohydrate?
tivozanib hydrochloride monohydrate (FOTIVDA) is a platelet-derived growth factor receptor beta inhibitor.
What is the brand name for tivozanib hydrochloride monohydrate?
FOTIVDA is a marketed brand name for tivozanib hydrochloride monohydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.